| Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de … R Guilhaumou, S Benaboud, Y Bennis, C Dahyot-Fizelier, E Dailly, ... Critical Care 23 (1), 1-20, 2019 | 310 | 2019 |
| Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment F Stanke-Labesque, E Gautier-Veyret, S Chhun, R Guilhaumou, ... Pharmacology & therapeutics 215, 107627, 2020 | 94 | 2020 |
| Amikacin in critically ill patients: a review of population pharmacokinetic studies A Marsot, R Guilhaumou, C Riff, O Blin Clinical pharmacokinetics 56, 127-138, 2017 | 72 | 2017 |
| Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity R Guilhaumou, C Solas, V Bourgarel-Rey, S Quaranta, A Rome, N Simon, ... Cancer chemotherapy and pharmacology 68, 1633-1638, 2011 | 54 | 2011 |
| Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples R Guilhaumou, C Solas, A Rome, M Giocanti, N Andre, B Lacarelle Journal of Chromatography B 878 (3-4), 423-427, 2010 | 43 | 2010 |
| Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence M Roustit, R Guilhaumou, M Molimard, MD Drici, S Laporte, JL Montastruc, ... Therapies 75 (4), 363-370, 2020 | 42 | 2020 |
| Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases R Guilhaumou, N Simon, S Quaranta, A Verschuur, B Lacarelle, N Andre, ... Cancer chemotherapy and pharmacology 68, 1191-1198, 2011 | 35 | 2011 |
| Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection N Venisse, G Peytavin, S Bouchet, MC Gagnieu, R Garraffo, ... Antiviral Research 181, 104866, 2020 | 29 | 2020 |
| Pediatric patients with solid or hematological tumor disease: vancomycin population pharmacokinetics and dosage optimization R Guilhaumou, A Marsot, J Dupouey, C Galambrun, A Boulamery, C Coze, ... Therapeutic drug monitoring 38 (5), 559-566, 2016 | 29 | 2016 |
| Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) F Lemaitre, M Grégoire, C Monchaud, S Bouchet, B Saint-Salvi, E Polard, ... Therapies 77 (5), 509-521, 2022 | 26 | 2022 |
| Effects of hydroxychloroquine on Covid-19 in intensive care unit patients: preliminary results A Lopez, G Duclos, B Pastene, K Bezulier, R Guilhaumou, C Solas, ... International journal of antimicrobial agents 56 (5), 106136, 2020 | 26 | 2020 |
| Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection P Giaime, M Guenoun, N Pedinielli, H Narbonne, JP Bergounioux, ... Nephrology Dialysis Transplantation 35 (8), 1346-1353, 2020 | 23 | 2020 |
| Levodopa in Parkinson’s disease: a review of population pharmacokinetics/pharmacodynamics analysis A Marsot, R Guilhaumou, JP Azulay, O Blin Journal of Pharmacy & Pharmaceutical Sciences 20, 226-238, 2017 | 19 | 2017 |
| Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultra‐high‐performance liquid chromatography tandem mass spectrometry method and its … J Dupouey, N Doudka, S Belo, O Blin, R Guilhaumou Biomedical Chromatography 30 (12), 2053-2060, 2016 | 19 | 2016 |
| French Society of Pharmacology and Therapeutics Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug … F Stanke-Labesque, E Gautier-Veyret, S Chhun, R Guilhaumou Pharmacol. Ther 215, 107627, 2020 | 18 | 2020 |
| External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients YL Wang, R Guilhaumou, O Blin, L Velly, A Marsot European Journal of Clinical Pharmacology 76, 1281-1289, 2020 | 16 | 2020 |
| Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid A Marsot, A Ménard, J Dupouey, C Muziotti, R Guilhaumou, O Blin British journal of clinical pharmacology 83 (5), 1039-1047, 2017 | 15 | 2017 |
| Serious neurological adverse events of ceftriaxone C Lacroix, AP Bera-Jonville, F Montastruc, L Velly, J Micallef, ... Antibiotics 10 (5), 540, 2021 | 14 | 2021 |
| Suivi thérapeutique pharmacologique du 5-fluorouracile: mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer F Lemaitre, F Goirand, M Launay, E Chatelut, JC Boyer, A Evrard, ... Bulletin du Cancer 105 (9), 790-803, 2018 | 12 | 2018 |
| Intrapleural administration of lipoplatin in an animal model ME Froudarakis, L Greillier, S Monjanel-Mouterde, A Koutsopoulos, ... Lung Cancer 72 (1), 78-83, 2011 | 12 | 2011 |
